Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer-Reference-Cited by-同舟云学术

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer

Published:2023-01-02 Issue:1 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Curran Desmond¹^ORCID,Patterson Brandon J.²^ORCID,Carrico Justin³^ORCID,Salem Ahmed¹^ORCID,La Elizabeth M.²^ORCID,Lorenc Stéphane¹^ORCID,Hicks Katherine A.³^ORCID,Poston Sara²^ORCID,Carpenter Christopher F.⁴⁵^ORCID

Affiliation:

1. Vaccines, GSK, Wavre, Belgium

2. Vaccines, GSK, Philadelphia, PA, USA

3. Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

4. Internal Medicine, Beaumont Hospital, Royal Oak, MI, USA

5. Internal Medicine, Oakland University William Beaumont School of Medicine, Rochester, MI, USA

Funder

GlaxoSmithKline Biologicals SA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2167907

Reference29 articles.

1. Annual incidence rates of herpes zoster among an immunocompetent population in the United States

2. Incidence of herpes zoster in patients with altered immune function

3. Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review

4. Risk of Herpes Zoster Prior to and Following Cancer Diagnosis and Treatment: A Population-Based Prospective Cohort Study

5. The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review;Medicine;2023-11-10

2. Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020-2021);Human Vaccines & Immunotherapeutics;2023-08